Search
Oruka Therapeutics Inc
ORKAAdd to Watchlist
85.210USD
-8.080-8.66%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.27BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-8.66%
5 Days
-5.95%
1 Month
+48.97%
6 Months
+201.41%
Year to Date
+181.13%
1 Year
+576.27%
Key Figures
90.840Open
91.780High
4.52MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
9.02%Turnover Ratio
93.290Prev. Close
82.220Low
308.72MTurnover
LossP/E Static
8.84P/B
0.00%Div Yield TTM
-26.37%ROA
91.00052wk High
2.68Volume Ratio
-83.72MNet Profit
50.17MShares
-2.3843EPS TTM
-0.23Beta
-27.50%ROE
10.63552wk Low
10.25%Amplitude
--Gross Margin
4.27BMarket Cap
10.84Reward/Risk
4.59%Risk Rate
TradingKey Stock Score of Oruka Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Oruka Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 141.31.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oruka Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Oruka Therapeutics Inc Highlights
StrengthsRisks
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -35.74, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 56.79M shares, increasing 10.95% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.26M shares of this stock.
Analyst Rating
Based on
14
analysts
Strong Buy
Current Rating
143.615
Target Price
+53.95%
Upside Space
Oruka Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oruka Therapeutics Inc Info
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Ticker SymbolORKA
CompanyOruka Therapeutics Inc
CEOKlein (Lawrence Otto)
Websitehttps://orukatx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Oruka Therapeutics Inc (ORKA)?
The current price of Oruka Therapeutics Inc (ORKA) is 85.21.
What is the symbol of Oruka Therapeutics Inc?
The ticker symbol of Oruka Therapeutics Inc is ORKA.
What is the 52-week high of Oruka Therapeutics Inc?
The 52-week high of Oruka Therapeutics Inc is 91.00.
What is the 52-week low of Oruka Therapeutics Inc?
The 52-week low of Oruka Therapeutics Inc is 10.63.
What is the market capitalization of Oruka Therapeutics Inc?
The market capitalization of Oruka Therapeutics Inc is 5.14B.
Is Oruka Therapeutics Inc (ORKA) currently rated as Buy, Hold, or Sell?
According to analysts, Oruka Therapeutics Inc (ORKA) has an overall rating of STRONG BUY, with a price target of 143.62.
What is the Earnings Per Share (EPS TTM) of Oruka Therapeutics Inc (ORKA)?
The Earnings Per Share (EPS TTM) of Oruka Therapeutics Inc (ORKA) is -2.31.